In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii

Clinical Microbiology and Infection

Volumn 18, Issue 4, 2012, Pages 383-387

  Vila Farres, X ^a   Garcia de la Maria, C ^a   Lopez Rojas R ^b   Pachon J ^b   Giralt, E ^a   Vila, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acinetobacter baumannii; Antimicrobial peptides; Colistin; Multiresistance; Susceptibility; Time killing curves

Indexed keywords

BACTENICIN; BETA DEFENSIN; BUFORIN I; CECROPIN; CECROPIN A; CECROPIN B; COLISTIN; HISTATIN 5; INDOLICIDIN; MAGAININ 2; MAGAININ I; MASTOPARAN; MELITTIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; PEPTIDE; WASP VENOM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR GENETICS; TIME;

ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLISTIN; DRUG RESISTANCE, BACTERIAL; INHIBITORY CONCENTRATION 50; MELITTEN; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; TIME FACTORS; WASP VENOMS;

EID: 84858703836     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03581.x     Document Type: Article

References (30)

1. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008; 9: 587-599.
2. Bergogne-Berezin E, Friedman H, Bendinelli M. Acinetobacter biology and pathogenesis, 1st edn. New York: Springer, 2008.
3. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010; 35: 219-226.
4. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008; 46: 1121-1122.
5. Pachon J, Vila J. Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Invest Drugs 2009; 10: 150-156.
6. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-238.
7. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010; 16: 35-40.
8. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 1210-1215.
9. Fournier PE, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2: e7.
10. Gallego L, Canduela MJ, Sevillano E et al. Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem. Enferm Infecc Microbiol Clin 2004; 22: 262-266.
11. Jain R, Danziger LH. Multi-drug resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38: 1449-1459.
12. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009; 3: 335-341.
13. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-487.
14. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multi-drug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-2950.
15. Reis AO, Luz DA, Tognim MC, Sader HS, Gales AC. Polymixin-resistant Acinetobacter spp. isolates: what is next? Emerg Infect Dis 2003; 9: 1025-1027.
16. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. The insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011; 55: 3022-3024.
17. Moffatt JH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54: 4971-4977.
18. Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53: 3628-3634.
19. Vila J, Sánchez-Céspedes J, Giralt E. Old and new strategies for the discovery of antibacterial agents. Curr Med Chem Anti-Infect Agents 2005; 4: 337-353.
20. Valencia R, Arroyo LA, Conde M et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009; 30: 257-263.
21. National Committee for Clinical Laboratory Standards/CLSI. Performance standards for antimicrobial disk susceptibility test: approved standard, 9th edn. A9. Wayne, PA: NCCLS/CLSI, 2006.
22. Isenberg HD. Clinical microbiology procedures handbook. Washington, DC: ASM Press, 2004.
23. Saugar JM, Rodriguez-Hernandez MJ, de la Torre BG et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother 2006; 50: 1251-1256.
24. Rodriguez-Hernandez MJ, Saugar JM, Docobo-Pérez F et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2006; 58: 95-100.
25. Moerman L, Bosteels S, Noppe W et al. Antibacterial and antifungal properties of α-helical, cationic peptides in the venom of scorpions from southern Africa. Eur J Biochem 2002; 269: 4799-4810.
26. Giacometti A, Cirioni O, Del Prete MS et al. Comparative activities of polycationic peptides and clinically used agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2000; 46: 807-810.
27. Cerovský V, Slaninová J, Fucík V et al. New potent antimicrobial peptides from the venom of Polistinae wasps and their analogs. Peptides 2008; 29: 992-1003.
28. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
29. Yandek LE, Pokorny A, Almeida PF. Wasp mastoparans follow the same mechanism as the cell-penetrating peptide transportan 10. Biochemistry 2009; 48: 7342-7351.
30. Li ML, Liao RW, Qiu JW, Wang ZJ, Wu TM. Antimicrobial activity of synthetic all-D mastoparan M. Int J Antimicrob Agents 2000; 13: 203-208.